No trading action warranted. This is a routine employee stock option grant with negligible dilution. Monitor next quarterly earnings for any changes to business fundamentals or guidance.
RDY drugs
RDY drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 22 $11.38entry
- T+1 · 4mo ago +3.69%α +4.93% · $11.80
- T+5 · 4mo ago +3.34%α +5.74% · $11.76
- T+20 · 3mo ago +6.41%α +3.52% · $12.11
- T+60 · 5w ago +13.36%α +10.09% · $12.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dr. Reddy's Laboratories filed a routine 6-K on July 22, 2026, disclosing the grant of 15,933 stock options to an eligible employee under the company's existing ESOP scheme. The options have an exercise price of Rs. 1,206 per share and vest 100% after three years. This is a standard compensation action with no material financial impact or new strategic information.
Key Facts
- Grant of 15,933 stock options to an eligible employee under the Dr. Reddy's Employees Stock Option Scheme, 2018.
- Exercise price set at Rs. 1,206 per share (fair market value).
- Options vest 100% at the end of 3 years.
- Filing is a routine disclosure under SEBI regulations; no new business or financial information.
Financial Impact
Immaterial, 15,933 options represent less than 0.002% of total outstanding shares (834,656,970 as of last 20-F).
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000514 |
| Document: 0001575872-26-000514-index.html | 0001575872-26-000514 |
| Document: 0001575872-26-000514.txt | 0001575872-26-000514 |
Track record
73 reports on RDY
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers